Previous 10 | Next 10 |
Tel Aviv, Israel, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, today announced the pricing of an underwritten public offering of 1,889,000 units, with each unit consisting of one American Depositary Shar...
Gainers: Amyris (NASDAQ: AMRS ) +43% . TMSR Holding (NASDAQ: TMSR ) +20% . Trevena (NASDAQ: TRVN ) +20% . Jason Industries (NASDAQ: JASN ) +17% . Evolus (NASDAQ: EOLS ) +16% . Urban One (NASDAQ: UONE ) +3% . Payment Data Systems (NASDAQ: PYDS ) +15% . Aileron Therapeutics (NAS...
TEL AVIV, Israel and ST. LOUIS , Feb. 5, 2019 /PRNewswire/ -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, today announced a collaboration with Washington University , a leading academic institution based in St. Louis, MO , aime...
TEL AVIV, Israel , January 28, 2019 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of a novel stem cell production technology, today announced it has concluded the scale-up development and manufacturing of clinical grade FasL in collaboration with its outsourced ...
Cellect Biotechnology (NASDAQ: APOP ) has filed to offer 4.65M units via AGP and Dawson James Securities. More news on: Cellect Biotechnology Ltd., Healthcare stocks news, Read more ...
Cellect Biotechnology (NASDAQ: APOP ) provides following milestone targets through Q2 2020. More news on: Cellect Biotechnology Ltd., Healthcare stocks news, Read more ...
TEL AVIV, Israel , Jan. 23, 2019 /PRNewswire/ -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a novel regenerative and cell therapy company with production technology, today provided its milestone targets through the second quarter of 2020. After achieving milestones during 2018, Cell...
TEL AVIV, Israel , Dec. 17, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, announced that KORIL-RDF, has approved Cellect's grant application, submitted with Cell2in, a Korean cell therapy company with whom a co...
TEL AVIV, Israel , Nov. 5, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of novel stem cell production technology, announced today that it has received a formal Notice of Allowance from the Japanese and Australian Offices for Patents & Trademarks (Japan...
TEL AVIV, Israel , Nov. 1, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP) , a developer of a novel stem cell production technology, announced today its CEO Dr. Shai Yarkoni will present at the 24 th Annual Bio Europe Conference which is being held in Copenha...
News, Short Squeeze, Breakout and More Instantly...
Cellect Biotechnology Ltd. Company Name:
APOP Stock Symbol:
NASDAQ Market:
Tel Aviv , Oct. 15, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: “APOP”) (the “Company”), announced today the record date and distribution date for the contingent value rights (the “CVRs”) to be distributed in connection with the...
Cellect Biotechnology Ltd (NASDAQ: APOP) shareholders approved the previously announced strategic merger agreement with Quoin Pharmaceuticals, the company said in a press release on Monday. Shares of the Israel-headquartered firm jumped about 50% this morning. The stock has now ...